Parameter | Bone metastatic disease (n = 62) | No bone metastatic disease (n = 151) | p value |
---|---|---|---|
PSA | |||
Mean PSA at primary diagnosis (ng/mL) | 264 (range:3–7000) | 35 (range:1–1000) | < 0.001b |
Median PSA at primary diagnosis (ng/mL) | 32 (IQR:16–118) | 14 (IQR:8–31) | |
Mean PSA at time of study inclusion (ng/mL) | 28 (range:0.1–173) | 14 (range:0.1–91) | 0.01b |
Median PSA at time of study inclusion (ng/mL) | 16 (IQR:5–35) | 9 (IQR:4–17) | |
Gleason grade groupsa | < 0.001c | ||
Gleason grade group 1 (Gleason score: 3 + 3) | 5 (8) | 24 (16) | |
Gleason grade group 2 (Gleason score: 3 + 4) | 6 (10) | 34 (23) | |
Gleason grade group 3 (Gleason score: 4 + 3) | 8 (13) | 35 (23) | |
Gleason grade group 4 (Gleason score: 4 + 4, 3 + 5, 5 + 3) | 14 (23) | 26 (17) | |
Gleason grade group 5 (Gleason score: 4 + 5, 5 + 4, 5 + 5) | 23 (37) | 30 (20) | |
NA | 6 (10) | 2 (1) |